Cefmenoxime kinetics during continuous ambulatory peritoneal dialysis. 1986

D A Sica, and R E Polk, and T M Kerkering, and P Patterson, and J Baggett

The kinetics of the aminothiazolyliminomethoxy cephalosporin, cefmenoxime, were determined after a 30 min intravenous infusion of 15 mg/kg body weight in 6 adult subjects undergoing continuous ambulatory peritoneal dialysis. Concentrations of cefmenoxime in serum, urine and dialysate were determined by high-pressure liquid chromatography. The mean peak serum concentration was 92.8 +/- 11.6 micrograms/ml and the harmonic mean for the elimination half-life was 5.46 h. The volume of distribution at steady-state was 14.60 +/- 3.01 l/kg. Total body clearance of the drug was 31 +/- 7.7 ml/min with 8 +/- 5% and 5.75 +/- 2.72% of the administered dose being eliminated by renal and peritoneal clearance, respectively. Peritoneal clearance for all exchanges (n = 24) was 1.93 +/- 68 ml/min. These data suggest that peritoneal losses of this drug are minimal and doses conventionally employed in advanced renal failure can be utilized in the management of systemic infections.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010531 Peritoneal Dialysis, Continuous Ambulatory Portable peritoneal dialysis using the continuous (24 hours a day, 7 days a week) presence of peritoneal dialysis solution in the peritoneal cavity except for periods of drainage and instillation of fresh solution. CAPD,Continuous Ambulatory Peritoneal Dialysis
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

D A Sica, and R E Polk, and T M Kerkering, and P Patterson, and J Baggett
July 1983, Clinical pharmacology and therapeutics,
D A Sica, and R E Polk, and T M Kerkering, and P Patterson, and J Baggett
November 1983, Clinical pharmacology and therapeutics,
D A Sica, and R E Polk, and T M Kerkering, and P Patterson, and J Baggett
June 1986, Drug intelligence & clinical pharmacy,
D A Sica, and R E Polk, and T M Kerkering, and P Patterson, and J Baggett
April 1986, Antimicrobial agents and chemotherapy,
D A Sica, and R E Polk, and T M Kerkering, and P Patterson, and J Baggett
August 1985, Antimicrobial agents and chemotherapy,
D A Sica, and R E Polk, and T M Kerkering, and P Patterson, and J Baggett
February 1984, Clinical pharmacology and therapeutics,
D A Sica, and R E Polk, and T M Kerkering, and P Patterson, and J Baggett
January 1983, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association,
D A Sica, and R E Polk, and T M Kerkering, and P Patterson, and J Baggett
July 1991, The Journal of laboratory and clinical medicine,
D A Sica, and R E Polk, and T M Kerkering, and P Patterson, and J Baggett
November 1983, Clinical pharmacology and therapeutics,
D A Sica, and R E Polk, and T M Kerkering, and P Patterson, and J Baggett
January 1981, Polskie Archiwum Medycyny Wewnetrznej,
Copied contents to your clipboard!